Form 4: Aclaris Therapeutics Executive Reports Stock Transaction
Insider Transaction (Form 4)
Roland Wilhelm Kolbeck, Chief Scientific Officer of Aclaris Therapeutics, Inc., reported multiple transactions in common stock on August 1, 2026.
Summary
- Option exercise/conversion: acquired 36,375 Common Stock on August 1, 2026; holds 36,375 after (Direct).
- Tax/exercise-price withholding: disposed of 12,385 Common Stock at $5.20 ($64,402) on August 1, 2026; holds 23,990 after (Direct).
- Option exercise/conversion: disposed of 36,375 Restricted Stock Units on August 1, 2026; holds 109,125 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Roland Wilhelm Kolbeck — Officer (Chief Scientific Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-01 | Option exercise/conversion | Common Stock | 36,375 | — | — | 36,375 |
| 2026-08-01 | Tax/exercise-price withholding | Common Stock | 12,385 | $5 | $64.4K | 23,990 |
| 2026-08-01 | Option exercise/conversion | Restricted Stock Units | 36,375 | — | — | 109,125 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-01 | Option exercise/conversion (36,375 shares) |
| 2026-08-01 | Tax/exercise-price withholding (12,385 shares) |
| 2026-08-01 | Option exercise/conversion (36,375 shares) |
Keywords
insider transaction, Form 4, ACRS, Aclaris Therapeutics, Inc., neutral, Roland Wilhelm Kolbeck
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.